AstraZeneca will present 19 abstracts, including 10 oral presentations and five late-breaking presentations, at the European Society of Cardiology (ESC) Congress from 25-28 August 2023, which includes data highlighting the opportunities for improved management in heart failure (HF), and AstraZeneca’s leadership across the interconnectedness of chronic diseases. Among these abstracts will be sub-analyses from the DELIVER trial – a trial …